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Objectives: These studies were performed to determine the effect of heparin
and nonanticoagulant heparin on myocardial function after ischemia-
reperfusion and to further evaluate the role that the nitric oxide–cyclic
guanosine monophosphate pathway plays in mediating the effect of heparin.
Methods: Fifteen dogs were subjected to 15 minutes ischemia followed by
120 minutes reperfusion and pretreated with either saline solution, bovine
heparin (6.0 mg/kg intravenously), or N-acetyl heparin (6.0 mg/kg intrave-
nously), a heparin derivative without anticoagulant properties. The left
anterior descending artery was occluded for 15 minutes and regional
systolic shortening, a unitless measure of myocardial contractility, assessed
during reperfusion. To evaluate the role of nitric oxide, the inhibitor
Nv-nitro-L-arginine, 1.5 mg/kg intracoronary, was given before heparin
administration. Myocardial levels of cyclic guanosine monophosphate, the
second messenger of nitric oxide, were also measured in the N-acetyl
heparin group using radioimmunoassay. Results: Regional systolic short-
ening was significantly decreased in the saline group during 60 and 120
minutes compared with before ischemia (9.2 6 1.0 and 9.0 6 0.9 vs 12.2 6
1.2, p <2 0.0003). Heparin and N-acetyl heparin–treated dogs, however,
showed preservation of systolic shortening throughout reperfusion. Admin-
istration of nitro-L-arginine significantly attenuated the protective effect of
heparin (9.2 6 1.2 vs 12.7 6 1.1, p <2 0.0001) and N-acetyl heparin (9.3 6
0.3 vs 12.8 6 0.4, p <2 0.0001) during 120 minutes reperfusion. Myocardial
levels of cyclic guanosine monophosphate were also significantly increased
in the N-acetyl heparin group compared with saline (199.1 6 7.1 vs 103.5 6
4.5 pmol/mg, p <2 0.0001). Conclusions: Heparin preserves myocardial
contractility after ischemia-reperfusion independent of its anticoagulant
properties. Furthermore, the protective effects of heparin during ischemia-
reperfusion are mediated, at least in part, through a nitric oxide–cyclic
guanosine monophosphate pathway. (J Thorac Cardiovasc Surg 1998;115:
440-9)
Brief episodes of myocardial ischemia followed byreperfusion are common clinical events in pa-
tients with coronary artery disease. These events
result in episodes of coronary endothelial and re-
gional myocardial dysfunction.1 This endothelial
dysfunction results in an impaired ability of the
endothelium to synthesize and release nitric oxide
(NO).2 Recent reports indicate an integral role for
NO released from both the endothelium of the
vasculature and the endocardium in the mainte-
nance of myocardial contractility.3, 4 Furthermore,
inhibition of NO synthesis has been demonstrated to
increase myocardial dysfunction after ischemia-
reperfusion (IR).5 These data indicate a critical role
for NO in both normal myocardial function and in
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the maintenance of myocardial function in the set-
ting of IR injury.
Pharmacologic preservation of myocardial func-
tion in the setting of IR injury remains a clinical
challenge. Heparin is widely used clinically as an
anticoagulant and has been demonstrated to protect
the myocardium in the setting of IR injury.6 Recent
reports have demonstrated increased levels of nitrite
and nitrate, the metabolites of NO,7 after heparin
administration in vivo. In the setting of myocardial
IR injury, preischemic administration of heparin
and heparin derivatives diminishes the extent of
myocardial infarct size.8
The rationale for this study stems from the obser-
vation that discontinuation or reversal of heparin in
patients at risk for myocardial ischemia after cardiac
catheterization or cardiopulmonary bypass, for ex-
ample, was occasionally associated with disastrous
myocardial dysfunction. We therefore hypothesized
that heparin may be regulating myocardial contrac-
tile function possibly independent of its anticoagu-
lant activity. We also hypothesized that the effect of
heparin may be mediated, in part, through modula-
tion of the NO pathway. Therefore the initial aims
of these studies were to establish the effects of
heparin and nonanticoagulant heparin on regional
myocardial function preservation in the setting of
brief IR injury. Subsequent studies were then per-
formed to explain the potential role of a heparin-
endothelial–derived NO pathway in the prevention
of myocardial dysfunction associated with IR injury.
Material and methods
Animals. Male mongrel dogs (25 to 35 kg) were used in
these studies. All experiments were approved by the
Georgetown Animal Care and Use Committee
(GUACUC) and conformed to the guidelines of the
“Guide for the Care and Use of Laboratory Animals”
prepared by the National Institutes of Health (NIH
Publication No. 85-23, revised 1985).
Materials: Bovine heparin, N-acetyl heparin and Nv-
nitro-L-arginine (L-NNA) were purchased from Sigma
Chemical (St. Louis, Mo.).
Surgical preparation. Animals were fasted overnight
before the operation with water available ad libitum.
Anesthesia was induced with sodium thiopental (25 mg/
kg, intravenous) and after endotracheal intubation the
lungs were mechanically ventilated. Anesthesia was main-
tained with halothane (1.5%) for the remainder of the
experimental period. Pancuronium bromide (0.1 mg/kg,
intravenous) was also administered to produce complete
muscle relaxation. Surgical preparation and collection of
data were performed at an inspired oxygen fraction of 1.0
and a respiratory rate of 10 to 13 ventilations/min. End-
tidal halothane, carbon dioxide, and arterial oxygen satu-
ration were continuously monitored with a POET agent
analyzer equipped with a pulse oximeter (Criticare Sys-
tems, Waukesa, Wis.). End-tidal carbon dioxide levels
were maintained between 33 and 37 mm Hg and end-tidal
halothane was maintained at 1.5% throughout the study.
Body temperature was maintained in the normothermic
range with a warming blanket.
A left thoracotomy was performed in the fifth intercos-
tal space and the heart was suspended in a pericardial
cradle. The left anterior descending (LAD) artery was
then exposed and dissected free of the myocardium
immediately distal to the first major diagonal branch. A
2.0 mm ultrasonic flow probe (Transonic Systems, Ithaca,
N.Y.) was positioned around the LAD artery distal to the
first diagonal for the continuous monitoring of LAD
artery flow with a Transonic T20 two-channel ultrasonic
blood flowmeter. A rubber vessel loop was then placed
around the LAD artery at this site and the free ends
passed through a narrow silicone rubber tube for use as a
snare to occlude the LAD artery.
A polyvinyl chloride catheter (Deseret Medical Inc.,
Sandy, Utah) was placed in the right femoral artery. A
high-fidelity pressure transducer (Millar Instruments, Inc.,
Houston, Tex.) was then placed through this catheter into
the aortic arch for measurement of aortic pressure. A
second transducer was placed in the left ventricle for the
continuous monitoring of left ventricular pressure. A pair
of ultrasonic dimension transducers (Vernitron, Bedford,
Ohio) were then implanted 10 to 12 mm apart in the inner
one third of the subendocardium of a region of the
anterior free wall of the left ventricle supplied by the LAD
artery to measure regional systolic shortening, a measure
of myocardial contractility.9 All animals were allowed at
least 15 minutes to stabilize after surgical instrumentation.
Experimental protocol
In vivo studies. Thirty animals were randomly assigned
to one of six treatment groups: saline, bovine heparin,
N-acetyl heparin, the NO synthase (NOS) inhibitor Nv-
nitro-L-arginine (L-NNA), L-NNA and bovine heparin,
and L-NNA and N-acetyl heparin. The treatment was
administered after instrumentation and before LAD ar-
tery occlusion. The dose of bovine heparin was deter-
mined on the basis of heparin dose-response curves
performed for each animal using the Hepcon HMS mi-
croprocessor (Medtronic HemoTec, Inc., Englewood,
Colo.). The dose of bovine heparin needed for each
individual dog was based on the endogenous level of
heparin in each animal and presented as a heparin level
(mg/kg) that was needed to achieve adequate anticoagu-
lation. The end point of our dosing was the circulating
heparin level needed to achieve adequate anticoagulation.
Heparin levels were checked every 15 minutes using the
Hepcon microprocessor and an appropriate level of hep-
arin was infused as a bolus to maintain the optimum
heparin level. The average dose of bovine heparin admin-
istered over the course of the protocol for all dogs was 6.0
mg/kg. Therefore the dose of N-acetyl heparin chosen was
also 6.0 mg/kg. This dose of N-acetyl heparin is also
consistent with the total dose administered in a similar
canine model of myocardial IR injury.8 The dose of
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L-NNA (1.5 mg/kg) was administered intracoronary to
selectively inhibit the NO pathway in the region of isch-
emia and to avoid the hemodynamic complications of
increased arterial and left ventricular pressure associated
with systemic administration consistent with previous ex-
periments performed by Duncker and Bache10 in a similar
canine model. L-NNA was administered 30 minutes before
heparin and N-acetyl heparin. Activated clotting times
and partial thromboplastin time were also measured as an
index of the degree of anticoagulation.
After treatment with either saline solution, bovine
heparin, or N-acetyl heparin, animals were subjected to 15
minutes of regional ischemia by LAD artery occlusion
followed by 120 minutes of reperfusion. Cessation of LAD
flow, wall motion changes, cyanosis of the anterior wall,
and typical electrocardiographic changes immediately af-
ter LAD artery occlusion were used as indices of success-
ful anterior wall ischemia. Hemodynamic measurements,
including regional systolic shortening, were recorded be-
fore ischemia and at 15, 60, and 120 minutes after
reperfusion.
Data collection and analysis. The signals from the
pressure transducers, ultrasonic flow probes, and sonomi-
crometry crystals were electronically processed by use of a
calibration control unit (Millar Instruments) and a Gould
transducer (model 13; Gould, Inc., Cleveland, Ohio). The
analog signals were subsequently amplified and converted
to digital signals at a sampling rate of 200 Hz. Analog
signals were also displayed on an oscilloscope (model
5B10; Tektronic, Beaverton, Ore.) for signal verification
throughout the experimental procedure. After experimen-
tation, stored signals were digitized and the data trans-
ferred for hemodynamic computations. Approximately 10
heartbeats were analyzed per intervention. Regional sys-
tolic shortening, a unitless measure of myocardial contrac-
tility, was determined using the following equation:
End-diastolic length – End-systolic length
End-diastolic length
3 100
where end-diastolic length is measured at the onset of the
left ventricular isovolumic contraction and end-systolic
length is measured at the maximum negative rate of
pressure rise (dP/dt). After the completion of the in vivo
experiments, the left ventricular myocardium in the dis-
tribution of the LAD artery was harvested in animals
exposed to saline or N-acetyl heparin, snap frozen in
liquid nitrogen, and stored at –80° C for cyclic guanosine
monophosphate (cGMP) analysis.
In vitro studies
cGMP levels in myocardium. Left ventricular myocar-
dium from ischemic and nonischemic regions was placed
in 0.1 mol/L hydrochloric acid and homogenized in a
Tissumiser (Tekmar, Cincinnati, Ohio). The homogenate
was then placed on ice for 30 minutes to extract cyclic
nucleotides. The homogenate was then centrifuged at
6500g for 30 minutes at 4° C and the resulting cytosolic
fraction analyzed for cGMP levels by means of radioim-
munoassay.11 In brief, cGMP standards (1 mmol/L) and
experimental samples were acetylated using an acetic
anhydride/triethylamine solution (1:2). A standard curve
was then generated using serial dilutions of 1 mmol/L
cGMP. cGMP antiserum (1:3,000 dilution) and
[125I]cGMP was then added to both the standards and
unknowns and incubated for a further 16 hours at 4° C.
The assay was stopped by the addition of 100 ml of 1%
g-globulin and 2 ml 25% polyethylene glycol. The samples
were then placed in a vortex before centrifugation at
7500g for 30 minutes at 4° C. The supernatant was then
aspirated and the pellet counted using a scintillation
counter. Myocardial cGMP levels were normalized to
protein content with serum albumin as a standard and
expressed in picomoles per milligram of myocardial pro-
tein.
To further explain the role of the NO-cGMP pathway
on the N-acetyl heparin–mediated effect, cGMP levels
were measured after 15 minutes ischemia and 120 minutes
reperfusion in a separate group of dogs (n 5 5) pretreated
with the NOS inhibitor L-NNA at the same intracoronary
dose of 1.5 mg/kg.
Coagulation parameters. Activated clotting times were
measured immediately before and 60 minutes after hep-
arin and N-acetyl heparin administration using a Hepcon
HMS microprocessor (Medtronic HemoTec). Blood sam-
ples were also assayed for the measurement of partial
thromboplastin time (Vet Research, Farmingdale, N.Y.).
Statistical analysis. Myocardial contractility during
reperfusion was compared with preischemic values within
each treatment group with a two-way analysis of variance
for repeated measures. Values after treatment with hep-
arin and N-acetyl heparin were compared with saline
control using a two-tailed unpaired Student’s t test. Myo-
cardial levels of cGMP after treatment with N-acetyl
heparin before and after IR injury were compared in a
similar manner. Measurements are reported as mean
values 6 the standard error of the mean.
Results
Myocardial contractility. Regional systolic short-
ening was significantly decreased in animals sub-
jected to IR injury alone during 60 and 120 minutes
reperfusion (p , 0.0003, Fig. 1). Groups that were
treated with bovine heparin and N-acetyl heparin
displayed preservation of regional systolic shorten-
ing throughout the entire period of reperfusion (Fig.
1).
NO inhibition. Intracoronary L-NNA did not sig-
nificantly increase hemodynamic parameters, which
are affected by systemic inhibition of NO (Table I).
LAD artery flow was also not significantly altered
after regional infusion of L-NNA (Table I). Regional
inhibition of NO with L-NNA caused a significant
decrease in regional systolic shortening during 60
and 120 minutes of reperfusion compared with
preischemia (p , 0.0001, Fig. 2, A and B). Inhibition
of NOS before IR injury, however, did not cause a
significant decrease in regional myocardial contrac-
tility during preischemia or during reperfusion com-
pared with IR alone (p 5 not significant, Fig. 2, A
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and B). However, the protective effect of bovine
heparin and N-acetyl heparin on regional myocar-
dial function during 60 and 120 minutes reperfusion
was abrogated after preadministration of L-NNA
(Fig. 2, A and B).
Myocardial levels of cGMP. Regional myocardial
levels of cGMP, the second messenger of NO, were
significantly decreased after 120 minutes reperfu-
sion compared with dogs that received saline solu-
tion in the absence of IR injury (103.5 6 4.5
Fig. 1. Regional systolic shortening during reperfusion after preischemic treatment with bovine heparin
and N-acetyl heparin. Groups represent preischemic treatment with saline solution (n 5 5), bovine heparin
(6.0 mg/kg, intravenous, n 5 5), and N-acetyl heparin (6.0 mg/kg, intravenous, n 5 5). Data are expressed
as means 6 the standard error of the mean. Asterisks indicate p , 0.0003 versus preischemic value within
each group. IR, Ischemia-reperfusion.
Table I. Hemodynamic profile before ischemia and treatment and during reperfusion in dogs treated with
saline (1), the nitric oxide synthase inhibitor nitro-L-arginine (L-NNA) alone (2), L-NNA with bovine heparin
(3), or L-NNA with the nonanticoagulant derivative, N-acetyl heparin (4)
Preischemia, pretreatment
120 Minutes reperfusion, posttreatment














HR 102.4 6 5.8 102.7 6 4.3 110.8 6 3.5 94.5 6 4.6 95.0 6 5.4 98.0 6 2.1 101.3 6 8.1 86.3 6 4.8
LAD flow 16.0 6 0.8 16.0 6 1.5 18.2 6 2.4 19.2 6 1.9 15.0 6 1.0 18.0 6 1.7 17.0 6 2.7 19.0 6 1.9
MAP 74.6 6 7.2 75.2 6 1.6 91.1 6 6.6 91.3 6 6.8 75.7 6 5.6 80.7 6 3.1 81.0 6 6.2 86.2 6 8.4
LVP systolic 85.2 6 6.5 85.0 6 1.4 99.2 6 6.5 106.6 6 6.6 80.4 6 5.5 87.8 6 3.6 90.2 6 6.7 97.2 6 7.4
LVEDP 10.8 6 2.7 7.3 6 1.8 11.2 6 1.3 12.6 6 2.2 7.5 6 2.9* 4.2 6 0.8* 6.8 6 0.8* 10.2 6 1.8*
RSS 12.2 6 1.2 11.5 6 0.4 12.7 6 1.1 12.8 6 0.4 9.0 6 0.9* 8.8 6 0.5* 9.2 6 1.2* 9.3 6 0.3*
Values presented as mean 6 standard error of the mean HR, Heart rate (beats/minute); LAD flow, left anterior descending artery flow (ml/min), MAP, mean
arterial pressure (mm Hg); LVP, left ventricular pressure (mm Hg); LVEDP, left ventricular end-diastolic pressure (mm Hg); RSS, regional systolic shortening
(unitless).
*p # 0.0003 comparing reperfusion with preischemia.
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pmol/mg vs 127.2 6 8.6 pmol/mg, p , 0.04). After
pretreatment with the nonanticoagulant heparin de-
rivative N-acetyl heparin, myocardial levels of
cGMP were increased compared with saline vehicle
alone in the absence of IR injury (127.2 6 8.6
pmol/mg vs 295.0 6 5.0 pmol/mg, p , 0.0001, Fig. 3,
A). In the setting of IR injury, pretreatment with
N-acetyl heparin caused a significant increase in
intramyocardial cGMP compared with IR alone
(103.5 6 4.5 pmol/mg vs 199.1 6 7.1 pmol/mg, p ,
0.0001, Fig. 3, A). Pretreatment with the NOS
inhibitor L-NNA significantly attenuated the in-
Fig. 2. Regional systolic shortening during 120 minutes of reperfusion after nitric oxide inhibition and
treatment with bovine heparin (A) or N-acetyl heparin (B). Groups represent preischemic treatment with
saline solution, bovine heparin, N-acetyl heparin, nitric oxide synthase inhibitor Nv-nitro-L-arginine
(L-NNA), L-NNA 1 bovine heparin, and L-NNA 1 N-acetyl heparin. There was an n 5 5 in each group.
The dose of bovine heparin and N-acetyl heparin was 6.0 mg/kg, intravenous. L-NNA (1.5 mg/kg) was
administered in an intracoronary fashion before heparin and N-acetyl heparin. Data are expressed as
means 6 the standard error of the mean. Asterisks indicate p , 0.0001 versus preischemic value within each
group. IR, Ischemia-reperfusion.
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crease in cGMP in the left ventricular myocardium
of groups treated with N-acetyl heparin in the
setting of IR injury compared with IR alone and IR
with N-acetyl heparin pretreatment (39.1 6 1.0
pmol/mg vs 103.5 6 4.5 pmol/mg and 199.1 6 7.1
pmol/mg, p , 0.0001, Fig. 3, B).
Coagulation profile. Activated clotting times and
partial thromboplastin time were significantly in-
creased above baseline in the bovine heparin-
treated groups (p , 0.05, Table II). Treatment with
N-acetyl heparin did not significantly alter any of the
coagulation parameters studied, indicating that this
heparin derivative was devoid of anticoagulant
properties (Table II).
Discussion
Heparin binds to antithrombin III, accelerating
the inhibition of thrombin and factor Xa resulting in
anticoagulation.12 In addition to its ability to inhibit
coagulation, it is now well established that heparin
also modulates several other physiologic processes.
We hypothesize a role for heparin in the preserva-
tion of myocardial function after IR injury, possibly
through an NO-dependent pathway. The present
data demonstrate, for the first time, that heparin
preserves myocardial function in experimental IR
injury by way of an NO-dependent pathway. Fur-
thermore, these effects are independent of the anti-
coagulant properties of heparin because N-acetyl
heparin, which posses no anticoagulant activity,
produced results similar to heparin.
One of the first physiologic processes that was
shown to be modified by heparin was the inflamma-
tory response. Heparin possesses several antiinflam-
matory properties, including the inhibition of poly-
morphonuclear leukocyte activation13 and inhibition
of complement activation.14 More recently, studies
have demonstrated that heparin modulates the re-
lease of numerous vasoactive factors released from
the endothelium, including endothelin and NO.7
Heparin’s ability to modulate both the inflammatory
response and the elaboration of endothelium-de-
rived vasoactive substance may explain, in part,
heparin’s protective role during reperfusion injury.
It has also recently been demonstrated that heparin
protects the myocardium after IR injury through its
ability to inhibit the complement cascade.8 The
ability of heparin to preserve myocardial contractil-
ity through the NO-cGMP pathway has not been
suggested as a possible protective mechanism of
action of heparin during IR injury.
After the identification of endothelium-derived
relaxing factor as NO,15 research has been per-
formed to identify the physiologic and pathologic
roles of NO. Within the vasculature, NO has been
identified as a key component in the maintenance of
Fig. 3. A, Cyclic guanosine monophosphate (cGMP) lev-
els in left ventricular myocardium after N-acetyl heparin
treatment and ischemia-reperfusion (IR) injury. Groups
represent treatment with saline solution (n 5 5), N-acetyl
heparin (6.0 mg/kg, intravenous, n 5 5), saline solution 1
IR injury (n 5 5), and IR injury 1 N-acetyl heparin (n 5
5). Data are expressed as means 6 the standard error of
the mean. Asterisks indicate p , 0.0001 for N-acetyl
heparin versus saline solution in the presence and absence
of IR. Asterisk indicates significance for IR injury versus
no IR injury in both the saline (p , 0.04) and N-acetyl
heparin treated groups (p , 0.0001). B, The group treated
with IR injury 1 L-NNA 1 N-acetyl heparin. Asterisk
indicates significance between L-NNA treated group ver-
sus IR injury and IR 1 N-acetyl heparin (p , 0.0001).
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vascular tone in the smooth muscle underlying the
endothelium,16 as well as in the inhibition of smooth
muscle cell proliferation.17 The role of the endothe-
lium in the paracrine modulation of myocardial
function has only recently become an area of exten-
sive study.3 Both types of cardiac endothelial cells
(coronary vascular and endocardial) regulate myo-
cardial contractility by releasing diffusable vasoac-
tive mediators, such as NO.18 Myocardial perfor-
mance has also been demonstrated to depend on an
intact and functional endocardial endothelium.19
The role that NO plays in the modulation of myo-
cardial contractility has been studied extensively in
different cardiac preparations and in humans. Nu-
merous in vitro studies have demonstrated that NO
depresses myocardial contractility in isolated guinea
pig cardiac myocytes and in isolated hamster papil-
lary muscles.20, 21 NO was also recently shown to
attenuate the positive inotropic response to b-ad-
renergic stimulation in humans with left ventricular
dysfunction.22
Despite the well-documented effect of NO as a
negative inotrope, recent studies suggest that endo-
thelium-derived NO and cGMP (the second mes-
senger of NO) in physiologic concentrations, are
associated with improved myocardial function and a
positive inotropic effect.23, 24 Mohan and associ-
ates23 report that the myocardial response to NO
and cGMP is a concentration-dependent biphasic
contractile response with low physiologic levels
stimulating contractility in isolated cat papillary
muscles, whereas high pathophysiologic levels result
in depressed contractility. These results were con-
firmed in rat cardiomyocytes exposed to organic
nitrates in which moderate increases in cGMP im-
proved the contractile response.24 Thus physiologic
levels of NO, most likely the result of stimulation of
endothelial constitutive NOS (ecNOS), result in a
positive inotropic effect, whereas pathophysiologic
levels of NO, the result of inducible NOS, classically
result in depressed contractility. Inducible NOS,
located in macrophages and vascular smooth mus-
cle, is activated by cytokines and endotoxin and
requires 6 to 12 hours to be expressed.25 Therefore
the pathophysiologic levels of NO present in such
conditions as cardiomyopathy, cardiac allograft re-
jection, and septic shock, where myocardial contrac-
tility is depressed, are most likely a result of induc-
ible NOS. In this study, the protective effect of
heparin and nonanticoagulant heparin is most likely
at the level of ecNOS, where physiologic levels of
NO and cGMP are beneficial to contractile function.
It is unlikely that our pharmacologic intervention is
inducing NO given the 2-hour time course of our
protocol.
The role of NO in IR injury has also received an
enormous amount of attention. NO-mediated vaso-
dilatation has been shown to be diminished after IR
injury.26 Furthermore, administration of NO donors
has been demonstrated to attenuate the deleterious
effects of IR injury on both endothelial27 and myo-
cardial function.28 Polymorphonuclear leukocytes,
which are prevalent during reperfusion injury, have
been demonstrated to mediate the myocardial con-
tractile dysfunction present during IR injury.29 Poly-
morphonuclear leukocyte–mediated myocardial
contractile dysfunction has also been recently dem-
onstrated to be diminished by administration of NO
donors.28 In this study, inhibition of NOS in the
setting of IR injury abolished the protective effect of
both heparin and nonanticoagulant heparin during
reperfusion injury (Fig. 2). In situations such as IR
injury, where the normal homeostatic function of
the endothelium is perturbed, diminished levels of
both NO and cGMP occur. We have demonstrated
that myocardial cGMP levels are significantly dimin-
ished during reperfusion injury, confirming the role
of NO in normal myocardial function and its distur-
bance during IR injury (Fig. 3, A). Thus it would be
logical to postulate that interventions that maintain
NO levels may prove beneficial in the maintenance
of normal endothelial and myocardial function.
Previous investigators have demonstrated that
heparin affords protection to the myocardium in the
setting of IR by reducing myocardial necrosis in
prolonged models of ischemia8 and improving he-
Table II. Coagulation parameters before and after treatment with bovine heparin and N-acetylheparin
Baseline Bovine heparin N-Acetyl heparin (Normal)
ACT 87.4 6 4.2 780.8 6 42.1* 77.6 6 11.9 (60-90 sec)
PTT 12.4 6 0.2 .100* 16.3 6 1.4 (10-25 sec)
Values presented as mean 6 standard error of the mean. ACT, activated clotting time (sec); PT, prothrombin time (sec); PTT, partial thromboplastin time
(sec).
*p # 0.001 compared with baseline values.
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modynamic factors associated with improved myo-
cardial function.30 The data in this study were
obtained using an acute episode of IR (15 minutes
of ischemia followed by 120 minutes of reperfusion).
This protocol better represents the clinical setting of
myocardial stunning in the absence of myocardial
necrosis. Using this technique, we demonstrated
that heparin preserves myocardial contractility by a
mechanism independent of its anticoagulant activ-
ity. Furthermore, we present a novel mechanism of
action of heparin and nonanticoagulant heparin in
affording myocardial protection by preserving the
NO-cGMP pathway that is critical for normal phys-
iologic function. An alternative pathway of cGMP
activation, such as through atrial natiuretic factor
stimulation of cGMP, is unlikely given that the
heparin-mediated increase in cGMP was abrogated
after treatment with L-NNA, indicating that heparin
is acting through the NO-cGMP pathway.
In conclusion, NO is critical for the preservation
of normal myocardial function, especially during
episodes of IR injury in which the NO-cGMP path-
way is perturbed. Furthermore, the administration
of heparin and heparin derivatives without antico-
agulant properties preserves the NO pathway and
prevents myocardial dysfunction after brief episodes
of IR. These data may prove clinically significant,
allowing the administration of heparin derivatives to
preserve myocardial function preventing further in-
jury in the absence of the adverse clinical complica-
tions of bleeding.
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Discussion
Dr. Pedro J. del Nido (Boston, Mass.). My first question
relates to whether you are looking at NO effects on
coronary vasculature, that is improved reperfusion, or are
you looking at direct myocardial suppressant effect of
NO? Most of us think of the latter being dependent on
very high concentrations of NO and is that in fact what
you are generating with these heparin derivatives?
Dr. Kouretas. First of all, I think it is both. I think it is
an effect of heparin on the endothelium-derived NO and
I also think it is an effect of heparin on myocardial levels
of NO. An enormous amount of literature suggests that
NO depresses myocardial contractility. However, after
carefully reviewing the literature, the levels of NO gener-
ated in those studies were very high, most likely resulting
from inducible NO. In our studies, we do not think that we
are dealing with inducible NO because our protocol is a
short period of ischemia (15 minutes) and reperfusion
(120 minutes). Therefore I do not think inducible NO is at
play because that takes 6 hours to be induced. We are
most likely observing the effect of constitutive venoarterial
NO.
Recent studies also indicate that physiologic levels of
NO elaborated by constitutive NO actually produce a
positive inotropic effect and not a negative inotropic
effect. Therefore we think that the positive inotropic effect
could be at two levels, both at the endothelial level of the
vasculature and at a direct myocardial level.
Dr. del Nido. And that leads to my follow-up question.
If, in fact, the heparin derivatives are increasing cGMP
production, can you give too much of this? In other words,
can you generate such a large amount of NO with these
medications that you actually lead to myocardial suppres-
sion?
Dr. Kouretas. First of all, I think to generate too much
NO you would probably have to induce NO. Heparin in
and of itself I do not think would cause that much NO to
be released. Therefore I think heparin is acting more at a
physiologic level (constitutive NO) than at pathophysio-
logic levels (inducible NO).
Dr. Frank W. Sellke (Boston, Mass.). It has been known
that heparin causes a release of endothelium-derived NO.
And in addition, other agents that cause the release of
NO, such as sodium nitroprusside and nitroglycerin, have
similar beneficial effects. Do you think this is a specific
effect of heparin or can it be expanded to any agent that
releases NO?
Second, heparin is a very potent inhibitor of comple-
ment activation. So there may be both an indirect effect of
myocardial preservation through the release of NO or a
direct effect by inhibition of complement activation.
Dr. Kouretas. The fact that so many studies have shown
that NO is beneficial in the setting of IR injury. I think the
fact that heparin releases NO is only one aspect of this
complicated puzzle. Heparin also has other properties
changing the variations of complement and as an “antiin-
flammatory” agent. Studies have also shown that inflam-
mation is a very important component in reperfusion
injury. So I think heparin can be acting at several levels, at
the level of NO, which is one area that we focused on, but
I think it is functioning at many levels. For example,
inhibiting inflammation in the setting of reperfusion injury
would be protective. It has also been shown to be a potent
antioxidant, free-radical scavenger, which is also impor-
tant in reperfusion injuries. So I think heparin can be
working on many levels and not just on NO. That is just
the area that we focused on.
Dr. John E. Mayer, Jr. (Boston, Mass.). As you probably
know, we have been interested in similar sorts of areas for
some time. As an additional way to confirm the role of
NO, have you thought about using L-arginine or some-
thing else that would increase endothelial production of
NO to see whether you can, in fact, offset the effect of your
NOS inhibitor?
Dr. Kouretas. We have not done those experiments.
That is a good suggestion to see whether we can replenish
endothelial function in the setting of reperfusion, but we
have not completed those studies at this time.
Dr. Brian Buxton (Heidelberg, Victoria, Australia). Pro-
tamine reverses the anticoagulant effect of heparin. Does
protamine abolish the preservation by nonanticoagulant
heparin of regional myocardial contractility after IR in-
jury? If so, this may explain at least in part the finding of
myocardial depression of protamine administration after
cardiopulmonary bypass.
Dr. Kouretas. A lot of investigators have speculated
that the effect of heparin is based on its highly negatively
charged structure. So one can speculate that protamine,
which is highly positively charged, might abrogate the
protective effect of heparin. On the flip side, other inves-
tigators have shown that protamine also releases NO. So
I think it is a very complicated question and needs to be
addressed.
Dr. Edward D. Verrier (Seattle, Wash.). I think the other
thing that is interesting is that NO really can be a
double-edged sword in IR. It would be very interesting to
see the inducible form of NO, which is up-regulated by
ischemia. Expression would take 4 to 6 hours to complete
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because controversy exists in the literature concerning the
efficacy of inducible NO with ischemia. It would be
interesting to see what would happen at 6 hours or 8 hours
to infarct size. The results may be different from the
conclusions of this presentation.
Dr. Gregory M. Hirsch (Halifax, Nova Scotia, Canada).
Some years ago I investigated heparin fragments for their
antiproliferative activity and in fact used various combi-
nations of fragment length and degree of carbon acetyla-
tion. I wonder whether you might comment on either
restrictions of size for the maintenance of this effect and
particularly describe the fragment and degree of acetyla-
tion that you used.
Dr. Kouretas. (Slide) The structure of heparin is one of
a repeating disaccharide unit. The structure of N-acetyl
heparin, the nonanticoagulant heparin derivative, has an
acetyl group placed instead of sulfate, which inhibits its
binding to antithrombin III. So basically this fraction of
heparin is the same length as regular bovine heparin with
only the substitution of this acetyl group. So this fraction
is actually the same length of bovine heparin that causes
the anticoagulant properties.
Bound volumes available to subscribers
Bound volumes of The Journal of Thoracic and Cardiovascular Surgery are available to subscribers (only) for the 1998 issues from
the Publisher, at a cost of $122.00 for domestic, $151.94 for Canadian, and $142.00 for international subscribers for Vol. 115
(January-June) and Vol. 116 (July-December). Shipping charges are included. Each bound volume contains a subject and author
index and all advertising is removed. Copies are shipped within 60 days after publication of the last issue of the volume. The binding
is durable buckram with the Journal name, volume number, and year stamped in gold on the spine. Payment must accompany all
orders. Contact Mosby, Inc., Subscription Services, 11830 Westline Industrial Drive, St. Louis, Missouri 63146-3318, USA; phone
800-453-4351 or 314-453-4351.
Subscriptions must be in force to qualify. Bound volumes are not available in place of a regular Journal subscription.
The Journal of Thoracic and
Cardiovascular Surgery
Volume 115, Number 2
Kouretas et al. 4 4 9
